Pharma is riding a vaccine high, but reputational risks loom

Suspensions of AstraZeneca’s jab because of blood clot concerns are a harbinger of challenges to come

17 March 2021 - 20:14 By Brooke Masters

Pharmaceutical companies have never had it so good. The rapid rollout of Covid-19 vaccines has made household names of Pfizer and AstraZeneca, and the industry is winning praise for cooperation.

But the decision this week by some governments to suspend use of the Oxford/AstraZeneca vaccine because of fears of possible blood clots shows just how fragile public trust can be. What has been a public relations triumph could, if handled badly, turn out to be a trap...

This article is reserved for Sunday Times subscribers.

A subscription gives you full digital access to all Sunday Times content.

Already subscribed? Simply sign in below.

Registered on the BusinessLIVE, Business Day or Financial Mail websites? Sign in with the same details.

Questions or problems? Email or call 0860 52 52 00.